TABLE 2.

Glycosolated haemoglobin (HgA1c): estimated percentage change by treatment status and response

	Phase I: 0–6 mo post-index		Phase II: 6–30 mo post-index		Phase III: >30 mo post-index
	Change (95% CI)	P	Change (95% CI)	P	Change (95% CI)	P
Full cohort (n = 384)
SVR	−5.4% (−7.3%, −3.5%)	<0.001	1.5% (0.5%, 2.6%)	0.003	0.5% (−0.6%, 1.7%)	0.337
TF	−0.6% (−4.4%, 3.4%)	0.773	0.1% (−1.1%, 1.4%)	0.838	−0.4% (−1.7%, 0.9%)	0.538
Untreated	−1.3% (−3.2%, 0.5%)	0.164	−0.0% (−0.6%, 0.6%)	0.927	0.0% (−0.6%, 0.6%)	0.974
Subcohorta (n = 306)
SVR	−4.9% (−6.9%, −2.8%)	<0.001	1.2% (0.1%, 2.4%)	0.034	0.5% (−0.9%, 1.8%)	0.506
TF	−1.2% (−3.4%, 1.0%)	0.290	0.1% (−0.6%, 0.9%)	0.710	−0.3% (−1.1%, 0.4%)	0.374
Untreated	−1.0% (−5.6%, 3.7%)	0.667	0.5% (−1.0%, 2.1%)	0.505	−0.9% (−2.6%, 0.8%)	0.279

CI, confidence interval; SVR, sustained virological response; TF, treatment failure.

^aSubcohort limited to patients with longitudinal BMI data.